Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cell therapy aims to make stem cell transplants safer for blood cancer patients

NCT ID NCT07216443

Recruiting now Disease control Sponsor: Orca Biosystems, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a new treatment called Orca-T for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Orca-T is a personalized cell therapy made from a donor's blood that includes stem cells and immune cells. The goal is to see if it can improve transplant success and reduce serious side effects like graft-versus-host disease. About 80 adults will take part in the study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Orca-T (a stem cell and T-cell therapy made from a donor's blood)

What this could lead to

If successful, Orca-T could offer a safer and more effective stem cell transplant option for people with blood cancers, reducing the risk of graft-versus-host disease and relapse.

What could go wrong

This is an early-phase trial with only 80 participants, so results may not apply to everyone. There are risks of infection, graft failure, or severe immune reactions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute disease acute myeloid leukemia bone marrow disorder disease Disease Attributes graft versus host disease hematologic disorder hematopoietic and lymphoid system neoplasm immune system disorder immunoproliferative disorder leukemia mixed phenotype acute leukemia myelodysplastic syndrome Myelodysplastic Syndromes neoplasm Neoplasms by Histologic Type Neoplasms by Site Pathologic Processes precancerous condition Preleukemia syndromic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE MIXED PHENOTYPE ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • John Theurer Cancer Center at Hackensack University Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Oregon Health and Science University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UCLA Department of Medicine

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Vanderbilt University, Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••